Negative regulation of translational elongation

Across TCGA pan-cancer cohorts, RNA activity of the Negative regulation of translational elongation pathway differs between tumor and matched normal tissue in 12 of the 18 cancer types tested.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LIHC and THCA, show the opposite pattern, with lower activity in tumor tissue.

LIHC, THCA, and COAD show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LIHC	Male	III,IV	−0.120	<.001	8	view →
THCA	Male	All	−0.072	<.001	8	view →
COAD	Female	II,III,IV	−0.057	<.001	7	view →
HNSC	Male	All	−0.030	.005	4	view →
READ	Male	All	−0.066	.034	3	view →
BLCA	All	IV	−0.038	.017	3	view →
CHOL	Male	All	−0.111	<.001	2	view →
ESCA	All	All	−0.086	.006	2	view →
STAD	Male	II,III,IV	−0.039	.008	2	view →
KIRC	All	All	−0.028	<.001	2	view →
LUSC	All	All	−0.023	.009	2	view →
LUAD	All	All	−0.017	.012	1	view →

Pink = more active in tumor, green = less active in tumor. Showing the 12 strongest of 12 lineages.

GO:0045900–LIHC

Open the LIHC breakdown →